Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Lysosomal storage of drugs may influence cancer treatment outcomes

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others.

17 Mar 2026

Study reveals new dual role of ezrin in osteosarcoma

Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin.

17 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

Psychiatrists’ use of biomarkers could open a new window into mental health diagnoses

Amanda Miller was 30 and pregnant with her second child in Hershey, Pennsylvania, when she developed depression.

17 Mar 2026

MGI Tech and Predica Diagnostics accelerate cervical cancer screening on DNBSEQ platforms

Achieving a major milestone, MGI and Predica Diagnostics enhance cervical cancer diagnostics with rapid, scalable HPV testing on advanced sequencing platforms.

From MGI 17 Mar 2026

Exercise cuts 'chemo brain' and fatigue in cancer patients

Implementing a simple exercise plan during chemotherapy may ease cognitive impairment and fatigue, promoting better health outcomes for cancer patients.

17 Mar 2026

New insight into origins of rare liver tumors in children

Liver cancer in children is rare, but when it occurs the two main types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC).

16 Mar 2026

New CAR-NKT cell therapy shows promise against aggressive endometrial cancer

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades.

16 Mar 2026

Doctors treating sickle cell disease report the highest burnout rates

Sickle cell disease specialists face higher burnout rates than peers, impacting patient care and highlighting the need for systemic support in healthcare.

16 Mar 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma

A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer.

16 Mar 2026

Exercise during chemotherapy supports physical and cognitive health

Researchers recommended a tailored, scientifically validated exercise program to individuals receiving chemotherapy for cancer, and those who were on a two-week chemotherapy schedule and followed the exercise prescription were able to maintain their walking-step goals, use resistance bands, and stay mentally sharper compared to patients who did not exercise.

13 Mar 2026

Robot-assisted system found to be feasible for diagnostic cerebral angiography

Digital subtraction angiography remains the gold standard for diagnosing cerebrovascular diseases, including intracranial aneurysms, arteriovenous malformations, and arterial stenosis.

13 Mar 2026

ESMO and EURACAN call for policy action to standardize care for patients with rare cancers

Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ESMO and EURACAN, the European Reference Network (ERN) for rare cancers.

13 Mar 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

13 Mar 2026

Experimental therapy eliminates pancreatic precancerous cells in mice study

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.

12 Mar 2026

Romiplostim prevents chemotherapy-induced thrombocytopenia in phase 3 trial

Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication romiplostim can effectively prevent chemotherapy from destroying platelet-producing bone marrow cells, a common complication known as chemotherapy-induced thrombocytopenia.

12 Mar 2026

Structured exercise helps chemotherapy patients maintain cognitive function and mental clarity

New research in the March 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an every two-week cycle.

12 Mar 2026

Personalized counseling program helps cervical cancer survivors quit smoking

A new study led by UCLA researchers suggests that a personalized counseling program can significantly help women who have survived cervical precancer or cervical cancer to quit smoking - and does so at a cost that researchers say represents good value for healthcare systems.

12 Mar 2026

Study reveals high burnout among doctors treating sickle cell disease

Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the two groups.

12 Mar 2026

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug conjugate (ADC) program.

From VALANX Biotech 12 Mar 2026